allosteric mutant IDH1/2 dual inhibitor
oral, brain penetrant, completed Ph. I in HV
from SBDD of prior mIDH inhibitor
ACS Med. Chem. Lett., 2020, 11, 101-107
Agios Pharmaceuticals, Cambridge, MA
AG-881
AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)